News and Trends 23 Nov 2017 The EU Gives €6.3M Grant to Anti-Cancer Consortium The consortium of companies will use the EU’s money to support the development of personalized therapies for breast and rectal cancers. Horizon 2020 is the biggest ever EU Research and Innovation program with almost €80B made available to take exciting science to the market. The initiative has awarded a €6.3M grant to a group of companies brought […] November 23, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2017 Welsh Scientists Use CRISPR to Engineer Cancer-Killing T cells Scientists at Cardiff University have used CRISPR/Cas9 genome editing technology to produce highly specific killer T cell receptors. Researchers at Cardiff University have replaced the regular receptors found on T cells with their own, which are geared up to better tracking down and killing cancer cells. The research reported in Blood explained how the group removed receptors that interact with immune cells […] November 22, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Nov 2017 British and German Scientists Chuck Proteins in the Trash to Uncover their Function Trim-Away removes a protein to uncover its true function, which will support disease research and potentially the development of new therapies. Scientists at the Medical Research Council in the UK and the Max Planck Institute in Germany have discovered Trim-Away, a new technique that can remove a protein from a cell so that its true function can […] November 20, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2017 British Biotech Gets Ready to Launch a New Antibiotic Drug to Fight Resistance Update (17/11/2017): Motif Bio will raise up to $20M (€17M) in the form of a loan from US firm Hercules Capital. The funds will be used to fund the pre-commercialization stage of iclaprim, a new antibiotic that is expected to be launched in the US in 2019. Originally published on 04/10/2017 Iclaprim is a new antibiotic […] November 17, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 16 Nov 2017 Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics Tusk Therapeutics is developing antibodies to ignite the immune system response against cancer. We spoke with CEO Luc Dochez about Tusk and the oncology field. Tusk Therapeutics, based just north of London, focuses on therapeutic antibodies to boost the immune system in the fight against cancer. The company has been developing a number of candidates […] November 16, 2017 - 6 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Nov 2017 New British Biotech Receives £3M to Develop Small Molecules that Fight Cancer NeoPhore, has received investment from Sixth Element Capital to develop small molecules that stimulate the immune system against cancer. Sixth Element Capital has invested £3M (€3.3M) in NeoPhore, a new spin-out from PhoreMost – a drug discovery company based in Cambridge, UK. NeoPhore has been set up to explore small molecules that could be used to stimulate […] November 15, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2017 This British Biotech Could Treat T-Cell Lymphoma without Leaving the Body Unprotected Autolus has revealed a new strategy to treat T-cell lymphoma without harming healthy, protective T cells. The therapy is expected to start human tests soon. T-cell lymphoma is a form of cancer that affects the cells responsible for protecting our body against infections. Unlike it’s done with cancer types that affect other blood cells, it’s […] November 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2017 British Biotech Gets a £2.5M Grant to Boost Cancer Immunotherapy Tusk Therapeutics is working on immunotherapies to ignite the immune system against cancer. The £2.5M grant will help it to accelerate their development. Tusk Therapeutics focuses on immuno-oncology to ‘harness the power’ of the immune system. One of its candidates is an antibody that targets the CD38 immune checkpoint, which is a marker of cell activation that […] November 14, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 Biotech Unicorn’s T-Cell Receptor Therapy “Nearly Doubles” Survival in Uveal Melanoma Immunocore, one of the only three European biotech unicorns, has presented Phase I results for its TCR immunotherapy IMCgp100 in patients suffering from metastatic uveal melanoma. Results are positive, but perhaps not to the level of expectation for a company with such a high valuation. On Saturday, Immunocore presented its latest clinical results at the Society […] November 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Nov 2017 British Biotech Gets PRIME Designation for its Brittle Bones Drug The EMA has awarded PRIME Designation to Mereo BioPharma’s osteogenesis imperfecta drug, a condition for which there is no treatment on the market. Mereo acquires, develops and commercializes therapies for patients with rare diseases. It was set up by Denise Scots-Knight, one of our top women entrepreneurs, in 2015 and already has a market cap […] November 13, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 9 Nov 2017 Meet the Spin-Out Queen Taking on Neurological Diseases Mary Kerr, CEO of NeRRe and Managing Director of KanDy, told us how its approaches could change the face of therapies for neuronal hypersensitivity and women’s health indications. Mary Kerr’s career has taken her through the rigorous world of big pharma, which she says gave her “the skillset… the development, the exposure and the opportunity to work […] November 9, 2017 - 4 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 8 Nov 2017 Interviewing Europe’s Most Intense Investor about Trends in Biotech I interviewed Kate Bingham of SV Health Investors about Alzheimer’s, checkpoint inhibitors, gender diversity and more at BIO Europe. BIO Europe 2017 was off to a racing start on Monday morning when I chatted with Kate Bingham, Managing Partner of SV Health Investors, formerly SV Life Sciences. Since she joined the firm in 1991, she […] November 8, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email